Bristol Myers Squibb

A few days ago, the Procurement (SS&P) and Innovation and Technology (IT) departments came together to broaden the technological horizons of everyone at Bristol Myers Squibb, organizing SWITCH, the first technology fair for Innovation at BMS Spain & Portugal.

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and delivers medicines for patients with serious diseases.

The Bristol Myers Squibb website privacy notice explains how the company keeps information safe.

Pathos AI secures **$237 million in Series E funding** at a **$3 billion valuation**, led by Bristol Myers Squibb with returning investors including AstraZeneca, NEA, and General Atlantic. The company uses its **Foundry AI platform**, which processes **200 petabytes of oncological data**, to identify high-potential drug candidates and optimize clinical trials. Pathos prioritizes its **JSKN016 cancer therapy** (an antibody-drug conjugate) and a joint **ER PROTAC program with AstraZeneca**. The funding also supports a **$55 million, five-year data licensing deal with Tempus AI** to advance neurological disease research, integrating anonymized patient data into Foundry for drug development.

Oct 2026SiliconANGLENews article

The company scheduled its third-quarter 2026 results announcement for late October.

Sep 2026Bristol Myers SquibbNews article

Bristol Myers Squibb receives accelerated FDA approval for the Zenbexus triple combination in relapsed multiple myeloma. The treatment is approved for patients as early as their first relapse.

Aug 2026Bristol Myers SquibbNews article

Bristol Myers Squibb reports expanded U.S. and European approvals for Opdivo (nivolumab) to treat classical Hodgkin lymphoma.

Mar 2026Bristol Myers SquibbNews article